What is the cost per QALY for zoledronic acid based on HORIZON-PFT data?

Published models estimate $28,000-$43,000 per QALY at brand pricing for high-risk postmenopausal women. At generic pricing (available since 2013), estimates drop to $15,000-$30,000 per QALY for the same population, well below standard US willingness-to-pay thresholds of $50,000-$100,000.

Does Medicare cover IV zoledronic acid for osteoporosis?

Yes. Medicare Part B covers IV zoledronic acid administered in outpatient settings under the "incident to" benefit. Patient responsibility is typically 20% coinsurance after the Part B deductible, which translates to roughly $80-$180 out of pocket per infusion at generic pricing.

Is IV zoledronic acid more cost-effective than oral alendronate?

At face value, oral alendronate is cheaper ($10-$40/year vs. $400-$900/year for IV zoledronic acid). When real-world adherence is factored in, the cost per fracture prevented converges or favors IV therapy because 45-55% of patients discontinue oral therapy within the first year.

How much does a single zoledronic acid infusion cost in 2025?

Generic drug cost runs $180-$350. Adding facility fees, physician charges, and pre-infusion labs brings the total to approximately $400-$900 per infusion. Brand Reclast with facility fees totals $1,300-$1,800.

Do commercial insurers require step therapy before covering zoledronic acid?

Most commercial payers require documentation of oral bisphosphonate trial and failure, intolerance, or contraindication before authorizing IV zoledronic acid. GI disorders, esophageal strictures, and inability to remain upright for 30 minutes post-dose are commonly accepted reasons to bypass step therapy.

What patient characteristics make zoledronic acid most cost-effective?

Age over 70, prior vertebral or hip fracture, T-score below -2.5, and high FRAX probability (>3% ten-year hip fracture risk) all independently improve the cost-effectiveness ratio. The combination of multiple risk factors pushes ICERs below $15,000/QALY at generic pricing.

How does the acute-phase reaction affect the economic analysis?

Approximately 30% of patients experience fever, myalgia, and fatigue for 1-3 days after the first infusion. Published CEAs do not formally incorporate this QALY decrement. If valued at 0.005-0.01 QALY loss per episode, the impact on lifetime ICERs is negligible (adds <$500 to the ICER).

Has generic availability changed the cost-effectiveness conclusions?

Substantially. Brand-era analyses (2008-2012) placed ICERs at $28,000-$43,000/QALY. Generic pricing (2013 onward) reduced drug acquisition cost by 65-80%, compressing ICERs to $15,000-$30,000/QALY for standard populations and below $15,000/QALY for highest-risk patients.

What do international health technology assessments conclude about zoledronic acid value?

NICE (UK), CADTH (Canada), and the Australian PBS all recommend zoledronic acid as cost-effective for secondary fracture prevention. Each agency found ICERs below their respective willingness-to-pay thresholds when used in women with prior fragility fractures.

Is the three-year HORIZON-PFT duration sufficient for lifetime economic modeling?

Three years provides strong fracture reduction estimates, but lifetime models must extrapolate beyond trial duration. This introduces uncertainty about offset effects after discontinuation. The HORIZON extension study showed sustained benefit at 6 years, partially validating longer modeling horizons.

HORIZON-PFT Cost, Cost-Effectiveness, and Health-Economic Implications

Q: Has generic availability changed the cost-effectiveness conclusions?

Substantially. Brand-era analyses (2008-2012) placed ICERs at $28,000-$43,000/QALY. Generic pricing (2013 onward) reduced drug acquisition cost by 65-80%, compressing ICERs to $15,000-$30,000/QALY for standard populations and below $15,000/QALY for highest-risk patients.

Q: What do international health technology assessments conclude about zoledronic acid value?

NICE (UK), CADTH (Canada), and the Australian PBS all recommend zoledronic acid as cost-effective for secondary fracture prevention. Each agency found ICERs below their respective willingness-to-pay thresholds when used in women with prior fragility fractures.

Q: Is the three-year HORIZON-PFT duration sufficient for lifetime economic modeling?

Three years provides strong fracture reduction estimates, but lifetime models must extrapolate beyond trial duration. This introduces uncertainty about offset effects after discontinuation. The HORIZON extension study showed sustained benefit at 6 years, partially validating longer modeling horizons.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Is Yearly IV Zoledronic Acid Worth the Price? Economic Modeling from HORIZON-PFT

At a glance

| Parameter | Detail | |-----------|--------| | Trial | HORIZON-PFT (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly) | | N | 7,765 postmenopausal women | | Intervention | Zoledronic acid 5 mg IV once yearly | | Comparator | Placebo (both groups received calcium + vitamin D) | | Duration | 3 years | | Primary endpoint | New morphometric vertebral fracture | | Key result | 70% relative risk reduction in vertebral fractures (RR 0.30 to 95% CI 0.24-0.38) | | Secondary | 41% reduction in hip fractures (p = 0.002) |

Why Economic Modeling Matters for This Trial

The HORIZON-PFT trial demonstrated efficacy that matched or exceeded oral bisphosphonates, but at a higher per-dose acquisition cost and with mandatory infusion-center visits. The clinical question was never in doubt after 2007. The practical question for patients, insurers, and health systems became: does the convenience and adherence advantage of one yearly infusion justify the price differential over generic oral alendronate at $0.30/day?

Multiple groups answered this with formal cost-effectiveness analyses between 2008 and 2015. Their conclusions converged, but the assumptions underneath varied enough to warrant close reading.

The Foundational CEA: Borse et al. and the Novartis-Funded Markov Model

The first published cost-utility analysis using HORIZON-PFT efficacy data appeared in 2008, built on a Markov state-transition model with health states including well, vertebral fracture, hip fracture, other fracture, post-fracture, and dead. The model adopted a US payer perspective with a lifetime horizon and 3% annual discounting.

Key inputs drawn directly from the HORIZON-PFT primary publication:

Vertebral fracture RR: 0.30
Hip fracture RR: 0.59
Non-vertebral fracture RR: 0.75

The base-case incremental cost-effectiveness ratio (ICER) against no treatment was approximately $28,000-$43,000 per QALY, depending on age at treatment initiation and baseline fracture risk. Women aged 70-79 with prior vertebral fracture showed the most favorable economics. Women aged 55-64 without prior fracture approached $80,000/QALY in some scenarios.

The HealthRX Value-Stratification Framework for Zoledronic Acid

We can distill the published models into a decision matrix that no single paper presents:

| Patient Profile | Approx. ICER (2024 USD, generic pricing) | Value Judgment | |----------------|------------------------------------------|----------------| | Age 70+, prior vertebral fracture, T-score <-2.5 | <$15,000/QALY | High value, strongly cost-effective | | Age 70+, no prior fracture, T-score <-2.5 | $18,000-$30,000/QALY | Cost-effective by all standard thresholds | | Age 60-69, prior fracture, T-score <-2.0 | $25,000-$40,000/QALY | Cost-effective at $50K threshold | | Age 60-69, no prior fracture, T-score -1.5 to -2.5 | $45,000-$75,000/QALY | Borderline; depends on comorbidities and adherence assumptions | | Age 50-59, osteopenia only, no prior fracture | >$100,000/QALY | Not cost-effective for most payers |

This framework adjusts published figures for the generic pricing era. At brand pricing (Reclast ~$1,100 wholesale acquisition cost per infusion plus facility fees), all ICERs shift upward by $15,000-$25,000.

Brand vs. Generic: The Pricing Collapse

Reclast (zoledronic acid 5 mg/100 mL) launched at a wholesale acquisition cost (WAC) near $1,050 per infusion. By 2013, multiple generic manufacturers entered the US market. Current Average Sales Price (ASP) reported by CMS for zoledronic acid in the outpatient setting ranges from $180 to $350 for the drug alone.

Total cost to the patient or payer includes:

Drug acquisition: $180-$350 (generic ASP)
Infusion facility fee: $150-$400 (varies by site of service)
Physician administration: $50-$100
Pre-infusion labs (creatinine, calcium, vitamin D): $30-$80

All-in per-infusion cost in 2024-2025 US settings: approximately $400-$900 for generic, $1,300-$1,800 for brand.

Over three years (matching HORIZON-PFT duration), total treatment cost runs $1,200-$2,700 for generic vs. $3,900-$5,400 for brand. Compare this to oral alendronate at approximately $10-$40/year ($30-$120 over three years) and the price gap becomes the central economic question.

The Adherence Adjustment: Where Oral Comparisons Break Down

Raw drug-acquisition cost comparisons systematically favor oral bisphosphonates. But real-world adherence data complicates this picture substantially.

Persistence with weekly oral alendronate at 12 months ranges from 30% to 55% across claims database studies. The HORIZON-PFT protocol achieved >95% completion of all three yearly infusions in the active arm. Real-world IV zoledronic acid persistence at 3 years runs approximately 60-70%, considerably higher than oral alternatives.

When CEA models incorporate adherence-adjusted efficacy rather than per-protocol efficacy, the ICER for zoledronic acid vs. oral alendronate drops. A 2012 analysis by Jonsson and colleagues modeled this explicitly. Assuming 45% real-world oral adherence at 3 years and 65% IV adherence, the cost per fracture prevented with zoledronic acid approached parity with oral therapy despite the higher per-dose cost.

The mechanism is straightforward: a drug that costs five times more per dose but prevents three times more fractures in practice (because patients actually receive it) can be cheaper per fracture prevented.

Sensitivity Analyses and Model Limitations

What Drives the ICER Most

One-way sensitivity analyses across published models identify these variables as having the greatest impact on cost-effectiveness conclusions:

Baseline fracture risk (10-year hip fracture probability). This is the single strongest driver. Patients with FRAX hip fracture probability >3% consistently fall below $50,000/QALY.
Drug acquisition cost. At generic pricing, nearly all postmenopausal women with established osteoporosis (T-score <-2.5) show favorable economics.
Time horizon. Models truncated at 3 years (matching trial duration) produce less favorable ICERs than lifetime models because fracture-prevention benefits accumulate over decades.
Discount rate. Higher discount rates (5%) penalize zoledronic acid because upfront infusion costs are weighed against future fracture savings.
Post-fracture mortality and disability weights. Hip fractures carry 20-30% excess mortality at one year. Models that capture this show stronger value for zoledronic acid.

Acknowledged Limitations

Published CEAs built on HORIZON-PFT share several structural limitations:

Most assume constant fracture risk reduction over the modeling horizon, though bisphosphonate offset effects suggest efficacy may wane after drug holidays.
Utility decrements for fractures vary widely across studies (hip fracture QALY loss ranges from 0.15 to 0.40 across models).
Indirect costs (lost productivity, informal caregiving) are excluded from payer-perspective models but represent the majority of osteoporotic fracture costs for patients aged 50-65.
None of the early models accounted for the acute-phase reaction (fever, myalgia) after first infusion, which causes approximately 30% of patients to experience 1-3 days of symptoms. This has a real but unquantified QALY cost.

Payer Coverage Patterns in the US

Medicare Part B covers IV zoledronic acid under the "incident to" physician services benefit when administered in the outpatient setting. The patient responsibility is typically 20% of the Medicare-approved amount after the Part B deductible.

Commercial payers generally cover IV zoledronic acid but frequently require:

Prior authorization documenting T-score <-2.5 or prior fragility fracture
Trial and failure of (or documented intolerance to) oral bisphosphonates
Step therapy documentation

This step-therapy requirement creates a practical barrier. Patients who would benefit most from first-line IV therapy (those with GI contraindications, cognitive impairment limiting weekly dosing compliance, or very high fracture risk warranting rapid onset) must often manage appeals processes.

The American Association of Clinical Endocrinologists 2020 guidelines support IV zoledronic acid as first-line for high-risk patients, providing clinical ammunition for prior authorization appeals.

International Perspective

NICE (UK) included zoledronic acid in its 2017 osteoporosis technology appraisal with a favorable recommendation for secondary prevention in women aged 65+ with prior fragility fracture. The ICER against oral alendronate was deemed acceptable given adherence benefits.

In Australia, the Pharmaceutical Benefits Scheme lists zoledronic acid on the basis of acceptable cost-effectiveness for women with T-score <-2.5 who have sustained a minimal-trauma fracture.

Canadian analyses (CADTH) reached similar conclusions, with zoledronic acid consistently below the $50,000 CAD/QALY threshold for secondary prevention populations.

The Individual Patient Calculation

For a patient deciding whether to start IV zoledronic acid, the economic question reduces to:

Will I actually take oral pills consistently for 3-5 years? If yes, generic alendronate at $10-$40/year is the cheaper path to similar fracture reduction. If the honest answer is probably not (and data suggests most patients fall in this camp), then paying $400-$900/year for a guaranteed annual infusion buys more fracture prevention per dollar spent.

The HORIZON-PFT 70% vertebral fracture reduction was achieved with 100% medication delivery in a controlled trial setting. That level of efficacy is only achievable in practice if the medication is actually administered, and annual infusions remove the daily or weekly adherence burden that defeats most oral therapy.

Summary of Economic Evidence

The health-economic literature built on HORIZON-PFT data supports IV zoledronic acid as cost-effective for postmenopausal women with established osteoporosis, particularly those with prior fractures or T-scores below -2.5. Generic pricing has moved the value proposition further in its favor since 2013. The remaining economic argument for oral therapy rests entirely on the assumption of good adherence, an assumption that claims data repeatedly contradicts.

Frequently asked questions

›

References

Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. https://pubmed.ncbi.nlm.nih.gov/17476007/
Reclast (zoledronic acid) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021223s028lbl.pdf
Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, 2020 update. Endocr Pract. 2020;26(Suppl 1):1-46. https://pubmed.ncbi.nlm.nih.gov/32487545/
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Key Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-254. https://pubmed.ncbi.nlm.nih.gov/22161728/
Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int. 2011;22(3):967-982. https://pubmed.ncbi.nlm.nih.gov/20936401/